๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer
NCT06325995Localized Prostate Cancer
Changhai Hospital
Not applicable
428
Shanghai
2024-02-01
Recruiting
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
NCT06447623Advanced Breast Cancer, HR+/HER2- Breast Cancer
DrugApatinib
Fudan University
Phase 3
184
Shanghai
2024-02-01
Recruiting
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
NCT04535843Myasthenia Gravis
Huashan Hospital
Observational
500
Shanghai
2024-02-01
Recruiting
ctDNA in HER2+ EBC Neoadjuvant Treatment
NCT07335081Breast Cancer
DrugsPyrotinib·Pertuzumab·Trastuzumab·Paclitaxel
Shanghai Jiao Tong University School of Medicine
Phase 2
60
Shanghai
2024-02-01
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
122
Beijing, Guangzhou, Henan, Shanghai, Sichuan, Wuhan
2024-02-01
Active, closed
12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
NCT07034222Alzheimer's Disease(AD)
Ruijin Hospital
Phase 4
80
Shanghai
2024-02-01
By invitation
The Novel Special Light for Endotracheal/Bronchial Lesions.
NCT07036614Tracheal Disease, Bronchial Disease
Shanghai Chest Hospital
Observational
400
Shanghai
2024-01-31
Recruiting
Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
NCT06911528Breast Cancer, Sentinel Lymph Node, Frozen Section, Cytology
Fudan University
Not applicable
709
Shanghai
2024-01-30
Active, closed
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
NCT05894889Stage IIIB(N2) Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Peking University
Phase 2
70
Beijing, Shanghai
2024-01-30
Recruiting
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
NCT06186726Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
Jian Chen
Phase 2
48
Shanghai
2024-01-26
Recruiting
Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC
NCT06251115Liver Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
9
Shanghai
2024-01-26
Active, closed
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
NCT06196840Neovascular Age-Related Macular Degeneration
DrugAflibercept
Innostellar Biotherapeutics Co.,Ltd
Phase 2
50
Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin
2024-01-24
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Pembrolizumab
AstraZeneca
Phase 1/2
161
Beijing, Guangzhou, Shanghai
2024-01-23
Recruiting
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
NCT06111612Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, Myeloid Sarcoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
50
Shanghai
2024-01-20
Active, closed
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Colitis, Ulcerative
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Active, closed
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
394
Guangzhou, Wuhan, Shenyang, Shanghai, Kunming
2024-01-19
Recruiting
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
NCT06130553Advanced Solid Tumors That Are MTAP Deficient
DrugsAZD3470·Datopotamab deruxtecan
AstraZeneca
Phase 1/2
334
Beijing, Chengdu, Shanghai, Wuhan
2024-01-18
Recruiting
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma
NCT06151743Locally Advanced Hypopharyngeal Carcinoma
DrugPemetrexed
Eye & ENT Hospital of Fudan University
Phase 2
32
Shanghai
2024-01-18
Active, closed
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
NCT05721950Non-small Cell Lung Cancer (NSCLC)
DrugBrigatinib
Takeda
Observational
154
Shanghai
2024-01-17
Recruiting
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
NCT06211790Kidney Cancer, Renal Cell Carcinoma, Renal Clear Cell Carcinoma
Fudan University
Phase 2
66
Shanghai
2024-01-16
Recruiting
WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
NCT06243003SCLC,Extensive Stage, Brain Metastases
Fudan University
Phase 1/2
56
Shanghai
2024-01-15
Recruiting
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
NCT06141369Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor
Shanghai Jiao Tong University School of Medicine
Not applicable
21
Shanghai
2024-01-13
Recruiting
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
NCT06267183Idiopathic Pulmonary Fibrosis
DrugSV001
Shanghai Synvida Biotechnology Co.,Ltd.
Phase EARLY_PHASE1
53
Shanghai
2024-01-12
Recruiting
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer
NCT06149689Pancreatic Adenocarcinoma
Fudan University
Phase 2
30
Shanghai
2024-01-10
Recruiting
Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease
NCT06978439Kawasaki Disease, Pilot Study, Coronary Artery Aneurysm, Rivaroxaban
DrugRivaroxaban
Children's Hospital of Fudan University
Phase 4
10
Shanghai
2024-01-10
Recruiting
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
NCT06123494HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
360
Shanghai
2024-01-09
Active, closed
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632Advanced or Metastatic Breast Cancer
DrugsExemestane·Everolimus·Fulvestrant
Pfizer
Phase 2
333
Wuhan, Changsha, Shanghai
2024-01-09
Recruiting
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
NCT06278454Unresectable Pancreatic Cancer, Advanced Pancreatic Cancer, Lymph Node Metastases
Chengdu New Radiomedicine Technology Co. LTD.
Phase 1
58
Zhengzhou, Suzhou, Shanghai, Chongqing, Tianjin
2024-01-09
By invitation
Efficacy of Vitamin B1 in Familial Adenomatous Polyposis Patients.
NCT06649825Familial Adenomatous Polyposis (FAP)
Shanghai Zhongshan Hospital
Not applicable
10
Shanghai
2024-01-08
Recruiting
Intervention for Children With Type 1 Diabetes Targeting Gut Microbes
NCT06198725Type 1 Diabetes
Children's Hospital of Fudan University
Not applicable
110
Shanghai
2024-01-08
Recruiting
Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)
NCT06238713Prostate Adenocarcinoma, Localized Prostate Carcinoma
Shanghai Changzheng Hospital
Not applicable
480
Shanghai
2024-01-08
Recruiting
Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial
NCT06091332Cavernous Malformations, Intracerebral Hemorrhage, Brainstem Stroke
DrugPaclitaxel
Huashan Hospital
Phase 2
75
Shanghai
2024-01-05
Recruiting
Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis
NCT06716281Knee Osteoarthritis
Shanghai IxCell Biotechnology Co., LTD
Phase 3
398
Shanghai
2024-01-05
Recruiting
Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
NCT06230055HER2-negative Breast Cancer, Leptomeningeal Metastasis
Fudan University
Phase 4
37
Shanghai
2024-01-05
Recruiting
A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating ฮฒ-thalassemia Major
NCT06465550ฮฒ-thalassemia
Shanghai BDgene Co., Ltd.
Phase 1
9
Guangzhou, Nanning, Shanghai
2024-01-05
Recruiting
Transthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer
NCT06503744Lung Cancer Stage IA
Shanghai Chest Hospital
Not applicable
110
Shanghai
2024-01-04
Active, closed
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT06079281Hypophosphatasia
DrugALXN1850
Alexion Pharmaceuticals, Inc.
Phase 3
124
Beijing, Changsha, Chengdu, Nanchang, Qingdao, Shanghai, Shenzhen
2024-01-03
Recruiting
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
NCT06950086HR-positive, HER2-negative Advanced Breast Cancer
TYK Medicines, Inc
Phase 1/2
180
Shanghai
2024-01-02
Recruiting
Mechanisms of Response to Therapeutic Intervention in Clinical High Risk (CHR) for Psychosis
NCT06542640Psychosis; Schizophrenia-Like, Healthy Controls
Beth Israel Deaconess Medical Center
Not applicable
300
Shanghai
2024-01-01
Not yet open
RAE Versus MIE in Patients With Esophageal Cancer After Neoadjuvant Therapy
NCT06012214Surgical Procedure, Unspecified
Shanghai Chest Hospital
Not applicable
300
Shanghai
2024-01-01
Recruiting
Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model
NCT06202404Metastasis, Predictive Cancer Model
Fudan University
Observational
166
Shanghai
2024-01-01
Active, closed
Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis
NCT06596941Iddvt, Pulmonary Embolism (PE)
Ruijin Hospital
Observational
800
Shanghai
2024-01-01
Recruiting
Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis
NCT07622212Deep Vein Thrombosis
RenJi Hospital
Observational
180
Shanghai
2024-01-01
Not yet open
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
NCT06166589Previously AG Chemotherapy Treated Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 2
19
Shanghai
2024-01-01
Recruiting
A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema
NCT06152107Severe Emphysema
Shanghai Chest Hospital
Not applicable
100
Zhengzhou, Beijing, Chengdu, Linyi, Nanchang, Shanghai, Shijiazhuang, Zhejiang
2024-01-01
Recruiting
The Effects of Remimazolam on the Incidence of Severe Hypoxia During Sedated Hysteroscopy for Assisted Reproduction in Overweight or Obese Patients
NCT06187896Hypoxia, Hysteroscopy, Overweight or Obesity
DrugsRemimazolam·Propofol
RenJi Hospital
Not applicable
600
Shanghai
2024-01-01
Active, closed
Hydroxychloroquine May be Beneficial for Preeclampsia
NCT06020378Pre-Eclampsia
DrugHydroxychloroquine
RenJi Hospital
Observational
462
Shanghai
2024-01-01
Active, closed
Quick Yielding Modified Short-Distance Fenestration Technique for the Treatment of Complex Aortic Arch Diseases: a Multicenter Single-Arm Objective Performance Criteria Trial(QYM-Tech Study)
NCT06639243Thoracic Aortic Dissection, Thoracic Aortic Aneurysm (true Aneurysm), Thoracic Pseudoaneurysm, Penetrating Aortic Ulcer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
87
Shanghai
2024-01-01
Recruiting
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy
NCT07561060Rectal Cancer
DrugsOxaliplatin·Capecitabine·Tislelizumab
Fudan University
Phase 1/2
50
Shanghai
2024-01-01
Recruiting
A New Cardiac Rehabilitation Treatment in the Application of Ischemic Heart Disease
NCT06681506Ischemic Heart Disease, Cardiac Rehabilitation
Shanghai 10th People's Hospital
Not applicable
100
Shanghai
2024-01-01
Recruiting
Bile Omics for Diagnosing Indeterminate Biliary Strictures
NCT07007832Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Strictures of Unknown Origin
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
260
Shanghai
2024-01-01
Recruiting
A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
NCT06300879Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
Huashan Hospital
Not applicable
30
Shanghai
2024-01-01
Not yet open
Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer
NCT06198387Oligo-metastatic Prostate Carcinoma
DrugsADT·Abiraterone
Changhai Hospital
Not applicable
30
Shanghai
2024-01-01
Recruiting
A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
NCT06158477Advanced Solid Tumors
Chengdu JOYO pharma Co., Ltd.
Phase 1
75
Shanghai
2024-01-01
Recruiting
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
NCT06218810Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab
DrugsFolfox·Cadonilimab·Bevacizumab
Fudan University
Phase 2
53
Shanghai
2024-01-01
Not yet open
Intraoperative Radiotherapy in Treating Spinal Metastases
NCT06093854Spinal Metastases
Shanghai Changzheng Hospital
Not applicable
132
Shanghai
2024-01
Not yet open
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
NCT06156267Pancreatic Cancer
DrugAdebrelimab
Fudan University
Phase EARLY_PHASE1
30
Shanghai
2024-01
Recruiting
Chinese PICU Collaborative Network on Pathogens and Drug Resistance of Severe Infections
NCT04923828Severe Infection
Children's Hospital of Fudan University
Observational
2,000
Shanghai
2023-12-31
Recruiting
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma
DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Rituximab
Bristol-Myers Squibb
Phase 1/2
460
Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Shanghai, Hangzhou
2023-12-29
Active, closed
Multi-parametric Ultrasound Versus Multi-parametric MRI for Prostate Cancer Detection
NCT06183905PROSTATE CANCER, Prostate Biopsy
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
635
Shanghai
2023-12-29
Recruiting
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
NCT06196736Advanced Urothelial Carcinoma
Drug9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3
432
Shanghai
2023-12-29
Recruiting
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
NCT06440902Colorectal Cancer Metastatic
Fudan University
Phase 2
1,100
Shanghai
2023-12-28
By invitation
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis
NCT06158490Moderate-to-severe Atopic Dermatitis
DrugJYP0061
Guangzhou JOYO Pharma Co., Ltd
Phase 2
120
Shanghai
2023-12-27
Recruiting
The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
NCT06081647Hypoxia, Gastric Polyp, Colon Cancer, Esophageal Cancer
RenJi Hospital
Not applicable
1,200
Nanjing, Nanchang, Jinan, Shanghai, Xiโ€™an, Tianjin, Hangzhou
2023-12-27
Recruiting
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
NCT06235229Multiple Myeloma
DrugGC012F
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis
NCT06406205Lupus Nephritis
Qilu Pharmaceutical Co., Ltd.
Phase 3
270
Bengbu, Bozhou, Hefei, Beijing, Fuzhou, Dalian, Shanghai, Changzhi
2023-12-25
Recruiting
Swartz Sheath With Angioplasty Guidewire-Assisted Technique for Patent Foramen Ovale Closure (STAGE-PFO)
NCT06793969Patent Oval Foramen
RenJi Hospital
Not applicable
120
Shanghai
2023-12-24
Active, closed
Spectacle Films Utilising S.T.O.P.ยฎ Technology for Slowing Down Myopia Progression in Children
NCT06137560Myopia
nthalmic Pty Ltd
Not applicable
210
Tianjin, Shanghai
2023-12-22
Active, closed
TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma
NCT06401447Esophageal Squamous Cell Carcinoma
Fudan University
Not applicable
50
Shanghai
2023-12-21
Active, closed
Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
NCT06180889Knee Arthroplasty, Total
DrugEnoxaparin
Suzhou Alphamab Co., Ltd.
Phase 2
241
Shanghai
2023-12-20
Not yet open
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
NCT06109402Stage II-IIIB(N2) Non-small Cell Lung Cancer
DrugsEtoposide·Nab-paclitaxel·Pemetrexed·Carboplatin
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
160
Shanghai
2023-12-20
Recruiting
Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors
NCT05916248Advanced Solid Tumor
DrugPersonalized neoantigen tumor vaccine
Ruijin Hospital
Phase EARLY_PHASE1
34
Shanghai
2023-12-20
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
DrugUpadacitinib
AbbVie
Phase 3
614
Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin
2023-12-19
Recruiting
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
NCT06166147Pancreatic Cancer
Fudan University
Observational
276
Shanghai
2023-12-18
Recruiting
Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
NCT06249308Ovarian Cancer
Fudan University
Observational
168
Guangzhou, Shenyang, Shanghai
2023-12-18
Active, closed
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
NCT06187506Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression
DrugDisitamab Vedotin
Fudan University
Phase 2
20
Shanghai
2023-12-18
Recruiting
Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
NCT06216782Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-12-16
Not yet open
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
NCT06152978Esophageal Squamous Cell Carcinoma
DrugSintilimab
Fudan University
Phase 2
182
Shanghai
2023-12-15
Recruiting
Atrophic Gastritis Predicts the Risk of Gastric Cancer
NCT06203327Atrophic Gastritis
Shanghai Jiao Tong University School of Medicine
Observational
2,042
Shanghai
2023-12-15
Recruiting
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
NCT06358222Carcinoma, Non-small Cell Lung Cancer
Shanghai Chest Hospital
Observational
200
Shanghai
2023-12-15
Active, closed
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323Prurigo Nodularis
DrugDupilumab
Sanofi
Observational
100
Guangzhou, Xi'an, Jinan, Hangzhou, Wenzhou, Beijing, Shanghai, Shenzhen
2023-12-12
Recruiting
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
NCT06042894Breast Cancer
DrugsSI-B003·Iza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
58
Shanghai
2023-12-12
Recruiting
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
NCT06253130Advanced Solid Tumor
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
NCT06375161B Cell Malignancies
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase EARLY_PHASE1
12
Shanghai
2023-12-11
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
DrugRisankizumab
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2023-12-11
Recruiting
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
NCT05965856Urothelial Carcinoma, Solid Tumor
DrugsSI-B003·Iza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2023-12-11
Recruiting
Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer
NCT06205927Non-small Cell Lung Cancer
Jian Chen
Phase 2
77
Shanghai
2023-12-07
Recruiting
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
NCT06069830NK-T-Cell Lymphoma, Extranodal
Ruijin Hospital
Not applicable
89
Shanghai
2023-12-06
Recruiting
A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT05969171Pancreatic Cancer Metastatic
Fudan University
Phase 2
65
Shanghai
2023-12-05
Recruiting
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983Breast Cancer
DrugsVinorelbine tartrate·JSKN003·Eribulin mesylate·Gemcitabine Hydrochloride
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
400
Guangzhou, Shanghai, Anyang, Baoding, Beijing, Changchun, Changde, Changsha
2023-12-01
Recruiting
Study on Deep Transcranial Magnetic Stimulation for Enhancing Insight
NCT06831877Impaired Insight
Shanghai Mental Health Center
Not applicable
138
Shanghai
2023-12-01
Recruiting
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
NCT05925452Active Systemic Juvenile Idiopathic Arthritis
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
290
Beijing, Chongqing, Changsha, Nanjing, Suzhou, Shanghai, Xiโ€™an, Chengdu
2023-12-01
By invitation
National Multicenter Registry for Pediatric End-Stage Heart Failure in China
NCT06927440Heart Failure, Children
Shanghai Jiao Tong University School of Medicine
Observational
1,000
Shanghai
2023-12-01
Not yet open
An Exploratory Study of Iliac Artery Branch Stent for Internal Iliac Artery Reconstruction in Abdominal Aortic Aneurysm/Iliac Aneurysm Repair
NCT06162273Aortic Aneurysm, Abdominal, Iliac Aneurysm
RenJi Hospital
Observational
40
Shanghai
2023-12-01
Recruiting
Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer
NCT07328945Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
250
Shanghai
2023-12-01
Recruiting
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
NCT06095141Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
Fudan University
Phase 2/3
30
Shanghai
2023-12-01
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
NCT06146946Rectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
1,384
Beijing, Shanghai, Chengdu
2023-12-01
Recruiting
Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
NCT06177301Nasopharyngeal Carcinoma
DrugsGX·GP·Tislelizumab
Fudan University
Phase 3
266
Shanghai
2023-12-01
Recruiting
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07266493Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Shanghai Zhongshan Hospital
Phase 2
26
Shanghai
2023-12-01
Rows per page Showing 2701–2800 of 3827
Previous 26 27 28 29 30 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=28

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.